期刊
CANCER RESEARCH
卷 72, 期 18, 页码 4672-4681出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-12-0228
关键词
-
类别
资金
- NIH/NCRR [UL1RR029882]
- California Institute for Regenerative Medicine [TG2-01169]
- Department of Defense [W81XWH-08-PCRP-IDA]
- NIH [1P30-CA138313]
- PCF Young Investigators Award
- BIRCWH grant [NIH/NICHHD 5 K12 HD001400]
- UCLA Jonsson Comprehensive Cancer Center Foundation Seed Grant
- Eli & Edythe Broad Center of Regenerative Medicine and Stem Cell Research Award
Elevation of the chromatin repression factor enhancer of zeste homolog (EZH2) is associated with progression and poor prognosis in several human cancers including prostate cancer. However, the mechanisms driving EZH2 expression are not fully understood. In this study, we investigated the functional synergy in prostate cancers in mice resulting from activation of the androgen receptor, Kras, and Akt, which drives three of the most frequently activated oncogenic signaling pathways in prostate cancer. Although, any two of these three events were sufficient to promote the formation and progression of prostate cancer, only the synergy of androgen receptor and Kras signaling could elevate EZH2 expression and expand prostate cancer progenitor cells in vivo. Our findings have revealed a genetic mechanism resulting in enhanced EZH2 expression during the progression of aggressive prostate cancer, with important implications for understanding how to target advanced disease where cancer progenitor cells may be critical. Cancer Res; 72(18); 4672-81. (C) 2012 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据